© 2012

Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma

  • Michael J. Murphy

Part of the Current Clinical Pathology book series (CCPATH)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Jochen Utikal, Jürgen C. Becker, Selma Ugurel
    Pages 9-18
  3. Paolo Antonio Ascierto, Maria Libera Ascierto, Mariaelena Capone, Zendee Elaba, Michael J. Murphy, Giuseppe Palmieri
    Pages 19-37
  4. Zendee Elaba, Michael J. Murphy, Philip Kerr, Jane M. Grant-Kels
    Pages 39-48
  5. Cheryl Bilinski, Avery LaChance, Michael J. Murphy
    Pages 49-67
  6. Giovanna Chiorino, Maria Scatolini
    Pages 79-88
  7. Suhu Liu, Suping Ren, Paul M. Howell Jr., Adam I. Riker
    Pages 89-112
  8. Jim Kozubek, Faseeha Altaf, Soheil Sam Dadras
    Pages 113-126
  9. Daniel W. Mueller, Anja K. Bosserhoff
    Pages 127-144
  10. Mark L. Steinberg
    Pages 145-157
  11. Steven J. Ohsie, Basil A. Horst, Alistair Cochran, Scott W. Binder
    Pages 159-176
  12. Basil A. Horst, Steven J. Ohsie, Alistair Cochran, Scott W. Binder
    Pages 177-188
  13. Michael J. Murphy, Karim Rezaul, David K. Han
    Pages 189-194
  14. Mel Ziman, Michael Millward, Robert Pearce, Mark Lee
    Pages 195-208
  15. Sandro Pasquali, Augustinus P. T. van der Ploeg, Simone Mocellin
    Pages 209-226
  16. Qiuzhen Liu, Marianna Sabatino, David F. Stroncek, Ping Jin, Francesco M. Marincola, Ena Wang
    Pages 227-241
  17. Hedwig Stanisz, Thomas Vogt, Knuth Rass
    Pages 247-263

About this book


This book describes both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, treatment planning, monitoring of response to therapy, identification of novel therapeutic targets and drug development. A broad range of biomarkers (DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein) is outlined. As therapies for melanoma become increasingly more target specific, the identification, validation and use of biomarkers will invariably play a greater role in the management of patients with this disease. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma is an essential resource for oncologists, dermatologists, dermatopathologists, general pathologists with an interest in melanoma, and melanoma researchers.


Epigenetic Biomarkers Lymph Node Disease Serological Disease microRNA Biomarkers

Editors and affiliations

  • Michael J. Murphy
    • 1
  1. 1.Health Center, Department of DermatologyUniversity of ConnecticutFarmingtonUSA

Bibliographic information

  • Book Title Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma
  • Editors Michael J. Murphy
  • Series Title Current Clinical Pathology
  • DOI
  • Copyright Information Springer Science+Business Media, LLC 2012
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-1-60761-432-6
  • Softcover ISBN 978-1-4939-6186-3
  • eBook ISBN 978-1-60761-433-3
  • Edition Number 1
  • Number of Pages XIV, 322
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Pathology
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals


From the reviews:

“This is a comprehensive overview of biomarkers as they relate to pathogenesis and clinical utility in the diagnosis, staging, and treatment of melanoma. … The audience is practitioners specializing in melanoma, including dermatologists, surgeons, and oncologists, as well as researchers in the field. … book broadly explores the role of molecular diagnostic techniques and specific biomarkers which may serve to facilitate more accurate diagnoses and identify early-stage melanoma patients with high risk for metastasis. … I highly recommend this book for melanoma clinicians and researchers.” (Susan M. Swetter, Doody’s Book Reviews, July, 2012)